Shares of CRISPR Therapeutics AG have moved 4.2% today, and are now trading at a price of $71.51. In contrast, the S&P 500 index saw a -1.0% change. Today's trading volume is 2,772,127 compared to the stock's average volume of 1,849,257.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Based in Zug, Switzerland the company has 458 full time employees and a market cap of $5,680,210,944.
The company is now trading -18.53% away from its average analyst target price of $87.78 per share. The 23 analysts following the stock have set target prices ranging from $42.0 to $220.0, and on average give CRISPR Therapeutics AG a rating of buy.
Over the last 52 weeks, CRSP stock has risen 37.0%, which amounts to a 22.0% difference compared to the S&P 500. The stock's 52 week high is $76.19 whereas its 52 week low is $37.55 per share. Based on CRISPR Therapeutics AG's average net margin growth of 41.7% over the last 6 years, its core business is on track for profitability and its strong stock performance may continue in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) |
|---|---|---|---|
| 2023 | 170,006 | -353,532 | -208 |
| 2022 | 1,198 | -650,175 | -54272 |
| 2021 | 914,963 | 377,661 | 41 |
| 2020 | 719 | -348,865 | -48521 |
| 2019 | 289,590 | 66,858 | 23 |
| 2018 | 3,124 | -164,981 | -5281 |
